123 related articles for article (PubMed ID: 37856763)
21. The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis.
Baldi GG; Brahmi M; Lo Vullo S; Cojocaru E; Mir O; Casanova M; Vincenzi B; De Pas TM; Grignani G; Pantaleo MA; Blay JY; Jones RL; Le Cesne A; Frezza AM; Gronchi A; Collini P; Dei Tos AP; Morosi C; Mariani L; Casali PG; Stacchiotti S
Oncologist; 2020 Nov; 25(11):e1777-e1784. PubMed ID: 32584482
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic options in inoperable ROS1-rearranged inflammatory myofibroblastic tumor of the tongue in a child: a case report and literature review.
Styczewska M; Patel A; Jaskulowska J; Godzinski J; Swieton D; Wasag B; Dass J; Bien E; Krawczyk MA
Anticancer Drugs; 2021 Nov; 32(10):1111-1115. PubMed ID: 34145176
[TBL] [Abstract][Full Text] [Related]
23. Alveolar soft part sarcoma in children and adolescents: The European Paediatric Soft Tissue Sarcoma study group prospective trial (EpSSG NRSTS 2005).
Brennan B; Zanetti I; Orbach D; Gallego S; Francotte N; Van Noesel M; Kelsey A; Casanova M; De Salvo GL; Bisogno G; Ferrari A
Pediatr Blood Cancer; 2018 Apr; 65(4):. PubMed ID: 29286582
[TBL] [Abstract][Full Text] [Related]
24. Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children's oncology group.
Smith LM; Anderson JR; Qualman SJ; Crist WM; Paidas CN; Teot LA; Pappo AS; Link MP; Grier HE; Wiener ES; Breneman JC; Raney RB; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Oct; 19(20):4058-64. PubMed ID: 11600608
[TBL] [Abstract][Full Text] [Related]
25. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.
Ke L; Xu M; Jiang X; Sun X
Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372
[TBL] [Abstract][Full Text] [Related]
26. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
27. A risk-based treatment strategy for non-rhabdomyosarcoma soft-tissue sarcomas in patients younger than 30 years (ARST0332): a Children's Oncology Group prospective study.
Spunt SL; Million L; Chi YY; Anderson J; Tian J; Hibbitts E; Coffin C; McCarville MB; Randall RL; Parham DM; Black JO; Kao SC; Hayes-Jordan A; Wolden S; Laurie F; Speights R; Kawashima E; Skapek SX; Meyer W; Pappo AS; Hawkins DS
Lancet Oncol; 2020 Jan; 21(1):145-161. PubMed ID: 31786124
[TBL] [Abstract][Full Text] [Related]
28. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
29. Inflammatory myofibroblastic tumors: recent progress and future of targeted therapy.
Nakano K
Jpn J Clin Oncol; 2023 Oct; 53(10):885-892. PubMed ID: 37394916
[TBL] [Abstract][Full Text] [Related]
30. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
31. Clinical characteristics and outcomes for children, adolescents and young adults with "CIC-fused" or "BCOR-rearranged" soft tissue sarcomas: A multi-institutional European retrospective analysis.
Sparber-Sauer M; Corradini N; Affinita MC; Milano GM; Pierron G; Carton M; Tirode F; Pissaloux D; Alaggio R; Vokuhl C; Bisogno G; Berlanga P; Ferrari A; Orbach D
Cancer Med; 2023 Jul; 12(13):14346-14359. PubMed ID: 37212486
[TBL] [Abstract][Full Text] [Related]
32. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion.
Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E
Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931
[TBL] [Abstract][Full Text] [Related]
33. Which Factors Are Associated with Local Control and Survival of Patients with Localized Pelvic Ewing's Sarcoma? A Retrospective Analysis of Data from the Euro-EWING99 Trial.
Andreou D; Ranft A; Gosheger G; Timmermann B; Ladenstein R; Hartmann W; Bauer S; Baumhoer D; van den Berg H; Dijkstra PDS; Dürr HR; Gelderblom H; Hardes J; Hjorth L; Kreyer J; Kruseova J; Leithner A; Scobioala S; Streitbürger A; Tunn PU; Wardelmann E; Windhager R; Jürgens H; Dirksen U;
Clin Orthop Relat Res; 2020 Feb; 478(2):290-302. PubMed ID: 31580267
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics of non-small cell lung cancer patients with EGFR mutations and ALK&ROS1 fusions.
Liu Q; Huang Q; Yu Z; Wu H
Clin Respir J; 2022 Mar; 16(3):216-225. PubMed ID: 35081265
[TBL] [Abstract][Full Text] [Related]
35. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
36. ROS1 fusions in cancer: a review.
Uguen A; De Braekeleer M
Future Oncol; 2016 Aug; 12(16):1911-28. PubMed ID: 27256160
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.
Chen YF; Hsieh MS; Wu SG; Chang YL; Yu CJ; Yang JC; Yang PC; Shih JY
J Thorac Oncol; 2016 Jul; 11(7):1140-52. PubMed ID: 27094798
[TBL] [Abstract][Full Text] [Related]
38. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?
Wiener ES; Anderson JR; Ojimba JI; Lobe TE; Paidas C; Andrassy RJ; Raney RB; Qualman SJ; Donaldson SS; Maurer HM; Link MP; Crist WM; Grier HE
Semin Pediatr Surg; 2001 Aug; 10(3):146-52. PubMed ID: 11481652
[TBL] [Abstract][Full Text] [Related]
39. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
[TBL] [Abstract][Full Text] [Related]
40. Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.
Furugaki K; Mochizuki M; Kohno M; Shu S; Harada N; Yoshimura Y
BMC Cancer; 2019 Apr; 19(1):301. PubMed ID: 30943926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
